Siti Zuhroh
Research Subjects
Research Interests
Siti Zuhroh has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Adityo Susilo
Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Special Capital Region of Jakarta.
2 shared publications - Ani Ruspitawati
DKI Jakarta Health District, Jakarta 10160, Indonesia
2 shared publications - Arif Syaiful Haq
DKI Jakarta Health District, Jakarta 10160, Indonesia
2 shared publications - Budi Setiawan
DKI Jakarta Health District, Jakarta 10160, Indonesia
2 shared publications - Dwi O. T. L. Handayani
DKI Jakarta Health District, Jakarta 10160, Indonesia
2 shared publications - Eka Yuli Safitri
DKI Jakarta Health District, Jakarta 10160, Indonesia
2 shared publications
Latest Publications
- Open Access
Epidemiology and Clinical Features of Mpox in Jakarta, Indonesia, August 2022–December 2023
Background/Objective: This study explores the epidemiology and clinical features of re-emerging mpox in Jakarta, Indonesia. Methods: This study used a retrospective study design to describe the epidemiological data, clinical features, and mortality of mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both the epidemiology and clinical features of mpox in people living with HIV (PLHIV) and in non-HIV patients (non-PLHIV). Results: Our study shows that, as of the end of December 2023, 59 mpox cases were treated in Jakarta. All of the mpox cases in Jakarta were diagnosed in males, mainly found in MSM (91.5%), and PLHIV (78%). Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group (22/59, 37.2%). Severe manifestations were found among PLHIV without antiretroviral therapy (ART). Conclusions: Mpox cases in Jakarta were all found in males and most of them were PLHIV. There are various manifestations of mpox; however, since immunosuppressed patients could present differently, a strong surveillance and vaccine notification system, cautious management, and spreading vaccination awareness are needed to prevent and treat mpox.
Open AccessEpidemiology and Clinical Features of Mpox in Jakarta, Indonesia, August 2022–December 2023
Background/Objective: This study explores the epidemiology and clinical features of re-emerging mpox in Jakarta, Indonesia. Methods: This study used a retrospective study design to describe the epidemiological data, clinical features, and mortality of mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both the epidemiology and clinical features of mpox in people living with HIV (PLHIV) and in non-HIV patients (non-PLHIV). Results: Our study shows that, as of the end of December 2023, 59 mpox cases were treated in Jakarta. All of the mpox cases in Jakarta were diagnosed in males, mainly found in MSM (91.5%), and PLHIV (78%). Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group (22/59, 37.2%). Severe manifestations were found among PLHIV without antiretroviral therapy (ART). Conclusions: Mpox cases in Jakarta were all found in males and most of them were PLHIV. There are various manifestations of mpox; however, since immunosuppressed patients could present differently, a strong surveillance and vaccine notification system, cautious management, and spreading vaccination awareness are needed to prevent and treat mpox.
- Open Access
- 22 November 2024
- Published by MDPI AG in Preprints.org
Epidemiology and Clinical Features of Mpox in Jakarta
Background/Objective: This study is to identify the epidemiology and clinical features of Mpox in Jakarta that just reemerged in Indonesia. Methods: This study used a cross-sectional study design to describe the epidemiological data, clinical features, and mortality of Mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both epidemiology and the clinical features of Mpox in HIV (PLHIV) and non-HIV patients (non-PLHIV). Results: Our study shows that as of the end of December 2023, 59 Mpox cases were treated in Jakarta. Mpox in Indonesia were mainly diagnosed in male, MSM, and HIV patients. Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group. Severe manifestations were found among PLHIV without ART. Conclusions: Mpox in Jakarta were found mainly in MSM, especially in PLHIV. There are various manifestations of Mpox, however, the clinical features were more severe in PLHIV without ART. Therefore, a strong surveillance system and spreading awareness regarding vaccination programme is needed to prevent the spread of Mpox. A cautious management was needed especially on PLHIV.
- 22 November 2024
- Published by MDPI AG in Preprints.org
Open AccessEpidemiology and Clinical Features of Mpox in Jakarta
Background/Objective: This study is to identify the epidemiology and clinical features of Mpox in Jakarta that just reemerged in Indonesia. Methods: This study used a cross-sectional study design to describe the epidemiological data, clinical features, and mortality of Mpox patients from August 2022 to December 2023. In addition, this study also aims to identify the differences in both epidemiology and the clinical features of Mpox in HIV (PLHIV) and non-HIV patients (non-PLHIV). Results: Our study shows that as of the end of December 2023, 59 Mpox cases were treated in Jakarta. Mpox in Indonesia were mainly diagnosed in male, MSM, and HIV patients. Most patients would manifest with fever, rash, and skin lesions. Syphilis was found as a concomitant infection in this group. Severe manifestations were found among PLHIV without ART. Conclusions: Mpox in Jakarta were found mainly in MSM, especially in PLHIV. There are various manifestations of Mpox, however, the clinical features were more severe in PLHIV without ART. Therefore, a strong surveillance system and spreading awareness regarding vaccination programme is needed to prevent the spread of Mpox. A cautious management was needed especially on PLHIV.